On July 28, 2010, VaxGen Inc. was acquired by diaDexus, Inc., in a reverse merger transaction. VaxGen, Inc. does not have significant operations. The company seeks to enter into a strategic transaction or series of strategic transactions. Previously, it was engaged in the development of vaccines that immunize against infectious disease. The company was founded in 1995 and was based in South San Francisco, California.
In the 1990s VaxGen developed, and began trials of, an AIDS vaccine called AIDSVAX. However, in 2003 it was announced that the preliminary trials of the vaccine, conducted in Thailand and Indianapolis, Indiana had been unsuccessful.
Vaxgen had focused its recent efforts on a new form of Anthrax Vaccine, for which it was awarded a $877 million contract to provide the vaccine under the Project Bioshield Act. In December 2006, HHS unilaterally withdrew the $877 million contract, sending the stock tumbling as low as $1.20 per share.
- "VaxGen to Acquire diaDexus in a Stock-for-Stock Merger Under Revised Terms". Diadexus.
- "BBC News article on the failure of the AIDSVAX trial". November 12, 2003. Retrieved January 6, 2010.
- "Community Medical Research Institute Begins Inoculations in AIDSVAX Trial".
- Williams, David (August 2, 2008). "Anthrax scientist Bruce Ivins stood to benefit from a panic". Los Angeles Times. Retrieved 2008-08-01. "Ivins is listed as a co-inventor on two patents for a genetically engineered anthrax vaccine, federal records show. Separately, Ivins also is listed as a co-inventor on an application to patent an additive for various biodefense vaccines."
Historically was http://www.VaxGen.com. This URL is no longer for the Vaxgen, Inc. in this article.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|